The global osteoarthritis therapeutics market is estimated to grow at a CAGR of 8.2% during the forecast period. Pipeline products are expected to offer an opportunity for the growth of the market. For instance, in April 2019, Pfizer Inc. and Eli Lilly and Co. declared a Phase III study outcomes assessing tanezumab 2.5 mg and 5 mg. This study was intended to compare the 16-week efficacy of tanezumab and long-term joint safety relative to nonsteroidal anti-inflammatory drugs (NSAIDs) among patients with moderate-to-severe osteoarthritis of the knee or hip. 5 mg treatment arm of the tanezumab met two from the three co-primary endpoints related to efficacy, showing a statistically potential improvement in physical function and pain than NSAIDs at the 16-week analysis.
To Request a Sample of our Report on Global Osteoarthritis Therapeutics Market: https://www.omrglobal.com/request-sample/osteoarthritis-therapeutics-market
However, patients who received 2.5 mg tanezumab did not experience a statistically potential improvement in physical function, pain, or overall assessment of patients for their osteoarthritis at 16 weeks than NSAIDs. Under the analysis for safety, there was a potential rate of events regarding joint safety in the tanezumab arms than NSAIDs at 80 weeks. As a monoclonal antibody, Tanezumab is part of an investigational drug class of non-opioid chronic pain medications referred to as nerve growth factor (NGF) inhibitors. These kinds of pipeline products with increased safety and efficacy are expected to offer an opportunity for the launch of new therapies in the future, which in turn, will likely drive the market growth.
Scope of the Global Osteoarthritis Therapeutics Market
Market Coverage
- Market number available for 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Anatomy and Drug Type
- Regions Covered- North America, Europe, Asia-Pacific, and Rest of the World
- Competitive Landscape- Pfizer Inc., Bayer AG, Zimmer Biomet Holdings, Inc., Sanofi S.A., and GlaxoSmithKline plc
(Get 15% Discount on Buying this Report)
A full Report of Global Osteoarthritis Therapeutics Market is Available at: https://www.omrglobal.com/industry-reports/osteoarthritis-therapeutics-market
Recent Strategic Initiatives in the Global Osteoarthritis Therapeutics Market
- In February 2020, GlaxoSmithKline plc declared the US FDA approval of Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID). It is an arthritis pain relief available as an OTC product to temporarily provide relief from arthritis pain in the knee, elbow, hand, ankle, wrist, or foot, in adults (18 years and older). With the approval of the US FDA, Voltaren Arthritis Pain becomes the first and only prescription-strength, NSAID topical gel for arthritis pain available OTC in the US. This approval will offer approximately 30 million Americans suffering from osteoarthritis OTC access to the topical treatment option.
- In January 2019, OrthogenRx, Inc. declared the introduction of TriVisc (sodium hyaluronate) to treat patients with osteoarthritic knee pain who have failed to get sufficient relief from physical therapy or exercise or simple painkillers. TriVisc is a highly purified hyaluronic acid (sodium hyaluronate; HA) solution and supports supplement the viscous properties of the fluid in the knee joint.
Key questions addressed by the report
- What is the market growth rate?
- Which segment/region dominates the market in the base year?
- Which segment/region will project the fastest growth in the market?
- How COVID-19 impacted the market?
Ø Recovery Timeline
Ø Deviation from the pre-COVID forecast
Ø Most affected region/segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Osteoarthritis Therapeutics Market-Segmentation
By Anatomy
- Knee
- Ankle
- Hip
- Hand
- Spine
By Drug Type
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Viscosupplementation Agents
- Corticosteroids
- Analgesics
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
